Abstract
The information of the complete genome sequences of Trypanosoma cruzi revealed that its genome contains nearly to 10,000 protein-coding genes. This vast amount of new information allows the identification of therapeutic targets in an accurate and undoubtedly forms. The current post-genomic period is a special moment in the anti-T. cruzi drug discovery and development ushering this moment as the anti-Chagas drug discovery era. In this review we describe, from a medicinal chemistry point of view, several identified potential biological targets for drugs development. We discuss the validity and druggability as anti-Chagas objectives of prenyl converting and transferring enzymes, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, triosephosphate isomerase, α-hydroxyacid dehydrogenases and trans-sialidase.
Keywords: Chagas' disease, enzymatic inhibitors, drugs development, Trypanosoma cruzi, ergosterol biosynthetic pathway, trypanothione reductase, farnesyltransferase inhibitors, cAMP-specific phosphodiesterases, Dipyridamole, sulfinyl radicals, glutathionylated products
Current Enzyme Inhibition
Title: Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Volume: 6 Issue: 4
Author(s): Alicia Merlino, Mercedes Gonzalez and Hugo Cerecetto
Affiliation:
Keywords: Chagas' disease, enzymatic inhibitors, drugs development, Trypanosoma cruzi, ergosterol biosynthetic pathway, trypanothione reductase, farnesyltransferase inhibitors, cAMP-specific phosphodiesterases, Dipyridamole, sulfinyl radicals, glutathionylated products
Abstract: The information of the complete genome sequences of Trypanosoma cruzi revealed that its genome contains nearly to 10,000 protein-coding genes. This vast amount of new information allows the identification of therapeutic targets in an accurate and undoubtedly forms. The current post-genomic period is a special moment in the anti-T. cruzi drug discovery and development ushering this moment as the anti-Chagas drug discovery era. In this review we describe, from a medicinal chemistry point of view, several identified potential biological targets for drugs development. We discuss the validity and druggability as anti-Chagas objectives of prenyl converting and transferring enzymes, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, triosephosphate isomerase, α-hydroxyacid dehydrogenases and trans-sialidase.
Export Options
About this article
Cite this article as:
Merlino Alicia, Gonzalez Mercedes and Cerecetto Hugo, Targets for Anti-T. cruzi Drugs in the Post-Genomic Era, Current Enzyme Inhibition 2010; 6 (4) . https://dx.doi.org/10.2174/157340810794578533
DOI https://dx.doi.org/10.2174/157340810794578533 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping
Current Molecular Pharmacology Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design The Role of Circadian Rhythms in Fatal Arrhythmias and the Potential Impact of Intervention for Sleep-Disordered Breathing
Current Pharmaceutical Design Genetic Polymorphism of Organic Anion and Cation Transporters: Pharmacokinetic and Pharmacodynamic Consequences in Pharmacotherapy
Current Pharmacogenomics Restoration of Cardiomyocyte Function in Streptozotocin-Induced Diabetic Rats after Treatment with Vanadate in a Tea Decoction
Current Pharmaceutical Biotechnology Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Novel Strategies to Delineate Matrix Metalloproteinase (MMP)-Substrate Relationships and Identify Targets to Block MMP Activity
Mini-Reviews in Medicinal Chemistry MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Atrial Fibrillation: Epidemiology and Peculiarities in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design